肌少症对头颈鳞癌预后价值的系统综述与荟萃分析
本系统综述与荟萃分析纳入 26 项研究、22408 例头颈鳞状细胞癌患者,评估肌少症及肌少症联合炎症的预后意义。结果显示肌少症显著降低总生存期和无病生存期,肌少症联合炎症进一步恶化生存。C3 与 L3 椎体水平评估肌少症的预后效能相当。
要点
- 阅片报告应关注头颈鳞癌患者骨骼肌减少,肌少症提示生存预后不良。
- 肌少症联合炎症状态对生存的负面影响更强,需重视炎性负荷。
- C3 与 L3 椎体水平评估肌少症的预后价值相近,可用于头颈影像评估。
核心结论
- 肌少症是头颈鳞状细胞癌患者生存率降低的独立相关因素。
- 肌少症联合炎症评估进一步降低总生存期和无病生存期,提示协同恶化预后。
- 基于 C3 与 L3 椎体水平的肌少症评估具有可比的预后效能。
研究设计与样本
- 系统综述与荟萃分析,检索 PubMed、Web of Science 与 Embase 数据库。
- 共纳入 26 项研究、22408 例患者,平均年龄范围 51 至 73 岁,男性占 85.5%。
- 采用随机效应模型计算合并风险比与 95% 置信区间,用 I² 统计量量化异质性。
- 通过敏感性分析、GOSH 图与亚组分析评估结果稳健性与异质性来源。
诊断标准与关键数值
- 肌少症与总生存期显著降低相关:合并风险比 1.89,P < 0.001。
- 肌少症与无病生存期显著降低相关:合并风险比 2.01,P < 0.001。
- 肌少症联合炎症评估进一步降低总生存期,合并风险比为 14.56,P < 0.001。
- 肌少症联合炎症评估进一步降低无病生存期,合并风险比为 5.92,P < 0.001。
- C3 与 L3 椎体水平对总生存期的合并风险比分别为 1.88 与 2.09,交互 P = 0.70。
临床应用与阅片要点
- 头颈鳞癌患者影像评估时应关注骨骼肌量变化,肌少症提示预后不良。
- 联合炎症指标可增强对生存预后的判断,报告时应关注炎性负荷相关表现。
- C3 与 L3 椎体水平均可用于肌少症评估,不同影像诊断标准具有可比预后价值。
局限性
- 肌少症的影像诊断标准尚缺乏统一标准化。
- 原始研究间存在异质性,需结合敏感性分析与亚组分析解释结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Sarcopenia is an established prognostic biomarker in malignancies, and its integration with inflammation demonstrates a synergistic amplification of adverse outcomes; its role in the prognosis of head and neck squamous cell carcinoma (HNSCC) remains inadequately characterized. The objectives of our study are to determine the prognostic value of combined sarcopenia and inflammation in HNSCC.
MATERIALS AND METHODS: A systematic search of PubMed, Web of Science, and Embase identified studies comparing survival outcomes among HNSCC patients stratified by the presence or absence of sarcopenia and concurrent inflammation. Pooled hazard ratio (pHR) and 95% confidence interval (CI) were calculated using random effect model. Heterogeneity was quantified using I² statistics, with sensitivity analyses, Graphic Display of Study Heterogeneity (GOSH) plots, and subgroup analyses to evaluate robustness and sources of heterogeneity.
RESULTS: 26 studies (22,408 patients; mean age range from 51 to 73 years; 85.5% male) were included. Sarcopenia was associated with significantly reduced overall survival (OS: pHR = 1.89; p < 0.001) and disease-free survival (DFS: pHR = 2.01; p < 0.001). Combined sarcopenia-inflammation assessment further reduced OS (pHR = 14.56) and DFS (pHR = 5.92; both p < 0.001). Prognostic utility was comparable across vertebral levels (C3 vs. L3): OS (C3: pHR = 1.88; L3: pHR = 2.09; interaction p = 0.70) and DFS (C3: pHR = 1.75; L3: pHR = 2.43; interaction p = 0.23).
CONCLUSION: Sarcopenia is independently associated with diminished survival rates in patients with HNSCC, and the additional value of inflammation synergistically exacerbates adverse clinical outcomes.
KEY POINTS: Question The impact of sarcopenia on head and neck squamous cell carcinoma (HNSCC) patients remains unclear, with a lack of standardized imaging diagnostic criteria. Findings HNSCC patients with sarcopenia exhibit poor prognosis, and inflammation further shortens survival, while different radiological diagnostic criteria demonstrate comparable efficacy. Clinical relevance Management of HNSCC patients should emphasize sarcopenia assessment and attention to inflammatory burden; reducing both risks may improve prognosis.
引用
- Zhang, Xu, Chai, et al. Sarcopenia as a prognostic factor in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Eur Radiol. 2026. PMID: 42429839. doi:10.1007/s00330-026-12754-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。